Fagron Berenberg Frankfurt Seminar

Rafael Padilla, CEO Karen Berg, Global IR Manager 9 June 2022



















Our Purpose

Together we enable pharmacists, prescribers, hospitals and the industry to provide quality, safety and service for their patients

We create value in healthcare by offering the entire range of products and services for compounding personalized medicine

Personalize medicine covers individual patient needs and increases effectiveness, quality and safety whilst reducing healthcare cost



Global leader in pharmaceutical compounding

FArmaceutische GRONdstoffen was founded in 1990

Present in 19 countries

Active in 35 countries

>3,000 people

3 divisions

the compounding value chain



Leading positions in all key markets

Favorable market dynamics and strong market positioning




MSCI ESG Rating






Uniquely integrated across the entire compounding value chain

Compounding overview







Our Products & Services



Essentials

- Raw materials for Compounding (GMP repackaging)
- Packaging & Supplies



Brands

- Semi-finished products & Vehicles
- Laboratory equipment & Compounding software
- Pharmacogenomic testing



Compounding Services

- Sterile & non-sterile compounding
- Outsourcing for pharmacies & hospitals
- Registration & licensing of compounded products




Academy

- Training & education
- Studies, innovations & concepts



Unrivalled global presence with increasing diversification





Expected mid-term growth of global compounding market ~6%








Global market to grow at ~6.0% CAGR over 2021 – 2026

Long-term secular drivers underpin market resilience





Strategic priorities to drive improved growth and value creation

Essentials	Brands	Compounding Services	
		Sterile	Non-Sterile
	Accelerate organic growth		Optimize non-sterile compounding business & positioning in the Netherlands
Continue broadening our product portfolio leveraging our innovation capabilities			
Maintain highest quality standards			
Increase operational efficiency	Organize brands globally and sell locally		
	Roll-out of Fagron Academy across all countries		
M&A	A to add incremental growth in North Amer	ica & EMEA	



Strategic ambitions underpinned by operational enablers



Global leadership in Brands & Essentials across our markets



Become leading, global, platform for sterile outsourcing services




Optimize non-sterile compounding and registration business



Build the organization of the future with a clear sustainability focus



Revenue growth to benefit from LFL in high-single digits





Growth upside from M&A opportunities

STRATEGIC CRITERIA



BUILDING OUT STERILE PLATFORM, CONSOLIDATE B&E



PRIORITIZE EMEA & NORTH AMERICA



EXPAND & DIVERSIFY PRODUCT PORTFOLIO



EXPLORE NEW THERAPEUTIC AREAS

WHAT WE PRIORITIZE

- Market share
- Strong commercial links
- Entrepreneurial approach
- Product assortment
- Synergies potential
- Partnerships
- Small to mid-size companies
- Buy & build approach



Drivers of future REBITDA margin profile



Average REBITDA margin consistent with 2017 – 21 average

Cash generation & earnings conversion to remain sustainably high

REBITDA margin

Continued benefits from asset light model

CAPEX to remain well under control

Consistent

Avg. REBITDA margin 2022-2026 10 – 11%

Operating Working Capital as a % of revenue

3% - 3.5%*

CAPEX as a % of revenue

+ (


≥ 70%


Operating cash conversion (% of REBITDA - 2022-2026)

≥ 50%

FCF conversion (% of REBITDA - 2022-2026)








Together we create the future of personalizing medicine.








Fagron Belgium

Warehouse



Fagron Lab

Equipment

















Compounding Services

Fagron Sterile Services US













Fagron Colombia

Fagron Family